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Abstract. Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric 
oxide production and involved in various pathological processes, especially processes 
involving cardiovascular risk. The purpose of this study was to analyze the correlation 
between ADMA and anthropometric, glucose, lipid, and inflammatory parameters. The 
study was analyzed by a cross-sectional study of 45 obese subjects at H. Adam Malik 
Hospital. Blood tests were carried out after 8-10 hours of fasting against cardiovascular 
risk: anthropometry (body weight, BMI, and WC), glucose (FPS, PPS, HbA1C, Fasting 
Insulin, and HOMA-IR), lipid (LDL-C, HDL-C, TG, and sd-LDL), and inflammation 
(ApoB and hs-CRP) parameters. The results showed of the 45 subjects, the average age was 
41.69 ± 5.69 years old, and the average BMI was 33.09 ± 5.05 (Obesity I). ADMA was also 
found to be correlated significantly with FPG, HBA1c, and TG parameters [r=-0.506, 
p=0.001; r=-0.334, p=0.013, dan r = -0.315.  p=0.017, respectively]. In obesity, ADMA 
correlated significantly with cardiovascular risk parameters: FPG, HbA1C, and TG. 
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Abstrak. Asymmetric dimethylarginine (ADMA) adalah penghambat endogen dari produksi 
oksida nitrat dan terlibat dalam berbagai proses patologis, terutama proses yang 
melibatkan risiko kardiovaskular. Tujuan dari penelitian ini adalah untuk menganalisis 
korelasi antara ADMA dan parameter antropometrik, glukosa, lipid, dan inflamasi. 
Penelitian ini dianalisis dengan studi cross-sectional pada 45 subyek obesitas di Rumah 
Sakit H. Adam Malik. Tes darah dilakukan setelah 8-10 jam puasa terhadap risiko 
kardiovaskular: antropometri (berat badan, BMI, dan WC), glukosa (FPS, PPS, HbA1C, 
Insulin Puasa, dan HOMA-IR), lipid (LDL-C, Parameter HDL-C, TG, dan sd-LDL), dan 
peradangan (ApoB dan hs-CRP). Hasil penelitian menunjukkan dari 45 subjek, usia rata-
rata adalah 41,69 ± 5,69 tahun, dan rata-rata BMI adalah 33,09 ± 5,05 (Obesitas I). 
ADMA juga ditemukan berkorelasi secara signifikan dengan parameter FPG, HBA1c, dan 
TG [r = -0.506, p = 0,001; r = -0,334, p = 0,013, dan r = -0,315. p = 0,017, masing-
masing]. Pada obesitas, ADMA berkorelasi signifikan dengan parameter risiko 
kardiovaskular: FPG, HbA1C, dan TG. 
Kata Kunci: ADMA, Obesitas, faktor risiko kardiovaskular  
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1 Introduction 
Asymmetrical dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase 
(NO) which appears as a risk marker for various disease conditions including end-stage kidney 
failure [1], liver failure [2], heart failure [3], diabetes [4], pre-eclampsia [5], and atherosclerotic 
[6]. It has been observed that ADMA is positively correlated with NO serum concentration and 
body mass index (BMI) [7]. 
Inflammation measured by C-reactive protein (CRP) is another strong risk marker for predicting 
cardiovascular death and complications including inflammatory diseases [8], sepsis [9], lung 
disease [10], and coronary heart disease [11]. The interaction between ADMA and CRP is a 
problem of cardiovascular disease because both ADMA and CRP factors are involved in 
endothelial dysfunction in humans [12]. 
Obesity increases the risk of morbidity due to hypertension, dyslipidemia, T2DM, coronary 
heart disease (CHD), stroke, gallbladder disease, osteoarthritis, sleep apnea, respiratory 
disorders, and certain types of cancer. Obesity is also associated with an increased risk of all 
causes of death due to cardiovascular disease (CVD) [13]. Obesity is caused by abnormal or 
excessive fat accumulation due to metabolic disorders [14]. According to previous research, the 
main determinant of obesity is insulin resistance which is associated with endothelial 
dysfunction [15]. Obesity can trigger the activity of tumor necrosis factor in α pro-inflammatory 
cytokine, which then inhibits the insulin receptor substrate 1 in the insulin signaling pathway 
[16]. 
Based on several studies, ADMA has a positive correlation with cardiovascular risk factors in 
prediabetes [17], angina pectoris [7], IGT, and obesity [18]. Therefore, the aim of this study was 
to investigate the correlation between ADMA and anthropometric, glucose, lipid, and 
inflammatory parameters in obesity. 
2 Method 
The study design was a cross-sectional study by recruiting 45 nurses at H. Adam Malik Hospital 
aged 30-55 years who met the criteria for obesity [19] and signed an informed consent form. 
Subjects were excluded from the study if they had secondary illness or obesity that could affect 
markers of metabolic disorders, lipid profiles, and inflammations such as pregnancy or lactation, 
acute infection, anemia, menopause, diabetes or hypertension, cardiovascular disease, chronic 
kidney disease or liver dysfunction, smoked, consumed corticosteroids, estrogen, beta-
adrenergic receptor agonists, nitrates, or other vasodilator agents [20]. Venous blood samples 
were collected from the subjects in the morning after 10-12 hours of fasting combined with 
ethylenediaminetetraacetate (EDTA) containing heparin, then centrifuged. 
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2.1 Biochemical Analysis 
Serum glucose levels, HDL cholesterol (HDL-C), and triglycerides (TG) were measured by the 
enzymatic colorimetric method while Apo-B and hs-CRP levels were measured by the 
immunoassay method with Hitachi Modular analyzer using the Roche Diagnostic kit. Insulin 
levels were measured by the chemiluminescence immunoassay method using the DPC 
Immulite-I analyzer (Diagnostic Products Corp, Los Angeles, CA, USA) kit. 
The HbA1c values were measured using the High-Performance Liquid Chromatography 
(HPLC) method which was in accordance with the American Diabetes Association standard 
[21]. ADMA levels were examined using ELISA method with a normal range of 0.4-0.75 
μmol/L (80-150 ng/mL) [22]. The HOMA-IR formula = [(fasting glucose serum (mmol / l) x 
fasting insulin (μU / ml) / 22,5] was used to determine the index of insulin resistance [23]. 
2.2 Statistical Analysis 
The mean and standard deviation were summarized as descriptive statistics. The Shapiro-Wilk 
test was used to determine whether a variable was normally distributed. The parametric test was 
performed on variables with normal distribution, whereas the nonparametric test was performed 
on variables with abnormal distribution. Furthermore, the Pearson and Spearman test was used 
to evaluate the correlation between variables according to the variable distribution. P < 0.05 was 
accepted as an indication of statistical significance. SPSS for Windows 22.0 was used for the 
statistical analysis.  
3 Results 
From the 45 obese patients who met the inclusion criteria, the average age was 41.69 ± 5.69 
years, and the average BMI was 33.09 ± 5.05 (Obesity I).  
Table 1. shows the characteristics of the research subjects in terms of anthropometric, glucose, 
lipid, inflammatory parameters in obesity, while Table 2. shows the correlation analysis 
between ADMA and the subject parameters. There was a significant correlation between the 
levels of ADMA and fasting blood glucose (FBG), HbA1c, and TG. 
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Table 1 Baseline Characteristic of Obesity Subjects 
Parameters Total (mean±SD); n=45 
Age  (years) 41.69±5.69 
Body weight  (Kg) 78.79±13.26 
BMI  (kg/m2) 33.09±5.05 
WC  (cm) 96.34±9.33 
ADMA  (umol/l) 0.82±0.13 
FPG  (mg/dl) 86.00±10.94 
PPG  (mg/dl) 109.84±28.56 
HbA1C (%) 5.56±0.56 
Fasting Insulin (μIU/mL) 9.52±7.32 
HOMA-IR  1.24±0.91 
LDL-C  (mg/dl) 137.51±33.51 
HDL-C (mg/dl) 47.06±12.84 
TG (mg/dl) 151.22±57.31 
sd-LDL (mg/dl) 1.34±0.26 
ApoB  (g/L) 104.31±18.41 
hs-CRP  (mg/L) 3.64±2.38 
Abbreviations: BMI, body mass index; WC, waist circumference; ADMA, asymmetric dimethylarginine; 
FPG, fasting plasma glucose; PPG, postprandial  plasma glucose; HbA1c, glycosylated hemoglobin; 
HOMA-IR: homeostasis model assessment of insulin resistance;; LDL-C, low density lipoprotein 
cholesterol; HDL-C, high density lipoprotein cholesterol; TG, triglycerides; ApoB: apolipoprotein B; sd-
LDL: small dense-LDL; CRP, C-reactive protein; 
In Table 2, After 12 weeks of lifestyle modification, there was decrease significantly on BW, 
BMI, WC, SBP, and chemerin in both groups. There was no decrease significantly of chemerin 
on both groups. 
Table 2 Relationship Between ADMA and Anthropometry, Glucose, Lipid, and 
Inflammation Parameters 
Abbreviations: BMI, body mass index; WC, waist circumference; FPG, fasting plasma glucose; PPG, postprandial plasma glucose; 
HbA1c, glycosylated hemoglobin; HOMA-IR: homeostasis model assessment of insulin resistance; LDL-C, low density lipoprotein 
cholesterol; HDL-C, high density lipoprotein cholesterol; TG, triglycerides; ApoB: apolipoprotein B; sd-LDL: small dense-LDL; 
CRP, C-reactive protein; 
* p<0.05. 
4 Discussion 
ADMA is believed to be a mediator that affects the risk of atherosclerosis. Several clinical 
studies have shown that increased ADMA is present in the conditions of chronic kidney 
Parameter r P 
Age (year) -0.057 0.356 
Body weight  (Kg) -0.056 0.407 
BMI  (kg/m2) -0.117 0.445 
WC  (cm) -0.100 0.256 
FPS  (mg/dl) -0.506 0.001*  
PPS  (mg/dl) -0.230 0.064 
HbA1C (%) -0.334 0.013* 
Fasting Insulin (μIU/mL) -0.102 0.255 
HOMA-IR  -0.225 0.069 
LDL-C  (mg/dl) -0.149 0.165 
HDL-C (mg/dl) 0.154 0.157 
TG (mg/dl) -0.315 0.017* 
sd-LDL (mg/dl) -0.042 0.392 
ApoB  (g/L) -0.168 0.135 
hs-CRP  (mg/L) -0.059 0.351 
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insufficiency, dyslipidemia, hypertension, diabetes mellitus, and hyperhomocysteinemia, and 
other conditions [24]. The presence of cardiovascular disease risk factors, especially 
atherosclerotic disease will induce functional and morphological changes in endothelium, 
become easily inflamed, thrombosis, and vasoconstriction [25]. The dysfunctional endothelium 
can be detected by an imbalance between widening and constricting factors, procoagulant 
factors, and anticoagulant factors which stimulate and inhibit the development and proliferation 
of cells [26]. 
Other clinical evidence also supported that increased plasma ADMA was associated with 
decreased NO synthesis [27]. Plasma ADMA levels can change rapidly in response to changes 
in the risk factors. In diabetic patients, a few hours after high-fat eating, plasma ADMA level 
increases, and vasodilation is reduced [28]. In low body mass index (BMI) condition, each 0.1 
μmol/L increase in the plasma ADMA level was associated with an increased risk of acute 
myocard infarct (AMI) with HR (95% CI) 1.21 (1.08-1.35) and cardiovascular death 1.30 (1.13-
1.49) [29]. ADMA level was 0.40-0.77 mol/L for the entire population, 0.41-0.79 mol/L for 
men, 0.38-0.73 mol/L for women under 45 years old, and 0.41-0.84 mol/L for women above 
45 years old [29]. Past studies showed that plasma ADMA levels were higher in obesity [30]. In 
this study, ADMA levels were 0.82 ± 0.13 mol/L. 
Based on several previous studies, plasma ADMA levels were associated with the risk of AMI 
and cardiovascular death [7], unchanged with weight loss in obesity [31], hypertension and 
insulin resistance [32], resistance insulin at the beginning of diabetes [33], HOMA-IR in 
prehypertension [34], BMI in overweight [35], and HOMA-IR in obesity [36]. In this study, 
ADMA had a significant correlation with FPG, HbA1c, and TG parameters [r = -0.506, p = 
0.001; r = -0.334, p = 0.013, and r = -0.315. p = 0.017, respectively] in obesity. 
5 Conclusion 
The association between ADMA and increased cardiovascular risks was related to glucose 
metabolism, lipid, and insulin resistance with various unknown mechanisms. Thus, further and 
extensive research should be done to determine the role of ADMA in the risk of cardiovascular 
disease. 
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